1cP-LSD

1cP-LSD (1-cyclopropanoyl-LSD, also marketed under the name Curie) is a synthetic psychedelic of the lysergamide family and an acylated derivative of LSD featuring a cyclopropanoyl group at the N1 position of the lysergamide core. It is firmly established as a prodrug for LSD: the cyclopropanoyl ester is cleaved by plasma and tissue esterases following ingestion, releasing pharmacologically active LSD. Human pharmacokinetic studies and the broader body of prodrug research for 1-acyl lysergamides support this mechanism. The subjective effects of 1cP-LSD are therefore the full LSD experience, with a delayed onset attributable to the conversion step.

Community reports uniformly describe 1cP-LSD as producing effects indistinguishable from LSD at peak, with an onset typically in the 60–90 minute range and duration of 8–12 hours. First-time users often note the slightly longer come-up compared to blotter LSD but report that peak effects and overall character are LSD in every meaningful sense. Experience reports describe a deep, immersive experience of 1cP-LSD at 150 μg as "legal lysergamide — identical to LSD-25" with the onset simply being 60–75 minutes rather than the 30–45 minutes typical of LSD directly.

1cP-LSD became one of the more widely available and better-documented LSD prodrug analogs, with a larger community knowledge base than many other members of the series. It has been used across the full spectrum of lysergamide applications — single large doses for profound psychedelic experiences, moderate doses for recreational and exploratory use, and microdosing protocols for mood and cognitive enhancement. Community reports note broad positive experiences with first-time moderate doses, describing "deep conversations" and "real introspection" alongside visual richness.

Testing with Ehrlich reagent remains essential to rule out dangerous adulterants. The risk profile is identical to LSD given the prodrug mechanism, with all the same contraindications and harm reduction principles applying.